Goldenrod Is Developing Next Generation Phosphodiesterase 4 Inhibitors
Brain-penetrant phosphodiesterase inhibitors for multiple neurological indications
About Us
Goldenrod Therapeutics is a portfolio company of Fannin based in Houston, Texas. We are committed to developing a next-generation phosphodiesterase 4 (PDE4) inhibitor designed to address serious neurological conditions, including Friedreich’s ataxia, other neurodegenerative diseases, substance use disorders (SUDs), and pain.
Earlier PDE4 inhibitors have been limited by side effects and tolerability challenges. This program is designed to overcome those limitations while achieving meaningful brain exposure, enabling a broader therapeutic window.
This approach has the potential to complement existing standards of care and expand treatment options for millions of patients with significant unmet medical needs worldwide.
Innovation
We are developing best-in-class small molecule drugs that are next-generation selective inhibitors of PDE4 enzymes.
Oral, brain-optimized small molecules designed for high CNS exposure and reliable target engagement.
Highly selective PDE4 inhibition for precise modulation of a validated neuroinflammatory pathway.
Drives both inflammation control and neurorestoration, addressing disease biology—not just symptoms.
Engineered for tolerability, avoiding the nausea and emesis that limited earlier PDE4 inhibitors.
News and Publications
